Auburn University College of Veterinary Medicine researchers are being featured at a national meeting for their collaborative work with Brazilian colleagues that suggests drinking the fermented milk beverage, kefir, may have a positive effect on blood pressure by promoting communication between the gut and brain.
Mirian Silva-Cutini, a doctoral exchange student from the University of Vila Velha in Brazil, and the first author of this work, presented the team’s findings at the American Physiological Society (APS) annual meeting at “Experimental Biology 2018” in San Diego. Silva-Cutini conducted her research at Auburn’s College of Veterinary Medicine under the direction of Dr. Vinicia Biancardi, an assistant professor in the Department of Anatomy, Physiology and Pharmacology.
Kefir is a fermented probiotic milk beverage known to help maintain the balance of beneficial bacteria in the digestive system. Previous research has shown that an imbalance in the gut’s colony of bacteria (microbiota) may cause high blood pressure in some people. Similarly, probiotics—live bacteria supplements that are beneficial to the digestive system—have been found to lower blood pressure, but the mechanisms by which this occurs are unclear.
The Auburn research team, in collaboration with the University of Vila Velha, studied three groups of rats to determine how kefir reduces high blood pressure (hypertension):
- One group had hypertension and was treated with kefir (“treated”);
- One group had hypertension and was not treated (“untreated”);
- One group had normal blood pressure and was not treated (“control”).
After nine weeks of kefir supplementation, the treated rats had lower levels of endotoxins (toxic substances associated with disruption in the cells), lower blood pressure and improved intestinal permeability when compared with the untreated group. Healthy intestines allow some substances to pass through, but generally act as a barrier to keep out harmful bacteria and other potentially dangerous substances. In addition, kefir supplementation restored the natural balance of different bacteria in the gut and within the brain, it diminishes inflammation and an enzyme essential for normal nervous system function, suggesting that the nervous and digestive systems work together to reduce hypertension.
“Our data suggests that kefir antihypertensive-associated mechanisms involve gut microbiota-brain axis communication during hypertension,” the researchers wrote.
The full-published abstract can be found at:
“Probiotic Kefir Antihypertensive Effects in Spontaneously Hypertensive Rats Involves Central and Peripheral Mechanisms. Mirian A. Silva-Cutini, Sarah C. Peaden, Francesca E. Mowry, Henri A.G. Ducray, Ludmila P. Globa, Iryna B. Sorokulova, Tadeu U. Andrade, and Vinicia C. Biancardi. Volume 32, Issue 1; Supplement.924.2; Apr 20, 2018”
About Experimental Biology 2018
Experimental Biology is an annual meeting comprised of more than 14,000 scientists and exhibitors from five sponsoring societies and multiple guest societies. With a mission to share the newest scientific concepts and research findings shaping clinical advances, the meeting offers an unparalleled opportunity for exchange among scientists from across the United States and the world who represent dozens of scientific areas, from laboratory to translational to clinical research. www.experimentalbiology.org
About the American Physiological Society (APS)
Physiology is the study of how molecules, cells, tissues and organs function in health and disease. Established in 1887, the American Physiological Society (APS) was the first U.S. society in the biomedical sciences field. The Society represents more than 10,500 members and publishes 15 peer-reviewed journals with a worldwide readership.